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Introduction
Efficacy of currently approved anti-HIV drugs is hampered
by mutations of the viral enzymes, leading invariably to
drug resistance and chemotherapy failure. Recent data
suggest that cellular co-factors also represent useful targets
for anti-HIV therapy. We have recently provided evidence
for the possibility to block HIV-1 replication by targeting
its cellular cofactor DDX3.
Material and methods
Molecular modeling and in silico technologies were
applied to rationally design small molecules specifically
targeting the RNA binding site of human DDX3. Bio-
chemical studies of mutated DDX3 enzymes were also
used to identify additional potential drug binding sites.
Results
Optimization of compounds identified by application of a
high-throughput docking approach afforded a promising
lead compound which proved to inhibit both the helicase
and ATPase activity of DDX3 and to reduce the viral
load of peripheral blood mononuclear cells (PBMC)
infected with HIV-1. A novel interaction site has been
also identified in DDX3, which, when blocked, can
reduce viral replication, representing an additional target
for small molecules inhibitors.
Conclusions
We have identified the first inhibitors of HIV-1 replication
targeting the RNA binding site of the cellular cofactor
human DDX3. These compounds may offer superior
selectivity over the ATP-competitive inhibitors previously
developed. In addition, a novel RNA interacting motif spe-
cific to DDX3 has been identified, opening new venues for
HIV-1 drug development.
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